160 related articles for article (PubMed ID: 35643306)
1. TNF-related apoptosis-inducing ligand, interferon gamma-induced protein 10, and C-reactive protein in predicting the progression of SARS-CoV-2 infection: a prospective cohort study.
Tegethoff SA; Danziger G; Kühn D; Kimmer C; Adams T; Heintz L; Metz C; Reifenrath K; Angresius R; Mang S; Rixecker T; Becker A; Geisel J; Jentgen C; Seiler F; Reichert MC; Fröhlich F; Meyer S; Rissland J; Ewen S; Wagenpfeil G; Last K; Smola S; Bals R; Lammert F; Becker SL; Krawczyk M; Lepper PM; Papan C
Int J Infect Dis; 2022 Sep; 122():178-187. PubMed ID: 35643306
[TBL] [Abstract][Full Text] [Related]
2. Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia.
Samaras C; Kyriazopoulou E; Poulakou G; Reiner E; Kosmidou M; Karanika I; Petrakis V; Adamis G; Gatselis NK; Fragkou A; Rapti A; Taddei E; Kalomenidis I; Chrysos G; Bertoli G; Kainis I; Alexiou Z; Castelli F; Saverio Serino F; Bakakos P; Nicastri E; Tzavara V; Kostis E; Dagna L; Koukidou S; Tzatzagou G; Chini M; Bassetti M; Trakatelli C; Tsoukalas G; Selmi C; Samarkos M; Pyrpasopoulou A; Masgala A; Antonakis E; Argyraki A; Akinosoglou K; Sympardi S; Panagopoulos P; Milionis H; Metallidis S; Syrigos KN; Angel A; Dalekos GN; Netea MG; Giamarellos-Bourboulis EJ
Cytokine; 2023 Feb; 162():156111. PubMed ID: 36529030
[TBL] [Abstract][Full Text] [Related]
3. Identifying patients with bacterial infections using a combination of C-reactive protein, procalcitonin, TRAIL, and IP-10 in the emergency department: a prospective observational cohort study.
van der Does Y; Rood PPM; Ramakers C; Schuit SCE; Patka P; van Gorp ECM; Limper M
Clin Microbiol Infect; 2018 Dec; 24(12):1297-1304. PubMed ID: 30268671
[TBL] [Abstract][Full Text] [Related]
4. Association of viral load with TRAIL, IP-10, CRP biomarker signature and disease severity in children with respiratory tract infection or fever without source: A prospective, multicentre cohort study.
Papan C; Argentiero A; Adams O; Porwoll M; Hakim U; Farinelli E; Testa I; Pasticci MB; Mezzetti D; Perruccio K; Simon A; Liese JG; Knuf M; Stein M; Yacobov R; Bamberger E; Schneider S; Esposito S; Tenenbaum T
J Med Virol; 2023 Jan; 95(1):e28113. PubMed ID: 36043485
[TBL] [Abstract][Full Text] [Related]
5. Temporal Dynamics of Host Immune Response Associated With Disease Severity and Time to Recovery in Patients Hospitalized for COVID-19.
Sophonsri A; Le D; Lou M; Ny P; Minejima E; Chambliss AB; Nieberg P; Shriner K; Wong-Beringer A
Crit Care Explor; 2022 Sep; 4(9):e0760. PubMed ID: 38371947
[TBL] [Abstract][Full Text] [Related]
6. Natural variability of TRAIL, IP-10, and CRP in healthy adults - The "HERACLES" study.
Langedijk AC; Rengerink KO; Harding E; Wensing A; van Slooten R; Israeli Y; Rosenberg M; Gottlieb T; Eden E; Bont LJ
Cytokine; 2024 Apr; 176():156530. PubMed ID: 38306791
[TBL] [Abstract][Full Text] [Related]
7. Expression of TRAIL, IP-10, and CRP in children with suspected COVID-19 and real-life impact of a computational signature on clinical decision-making: a prospective cohort study.
Fröhlich F; Gronwald B; Bay J; Simon A; Poryo M; Geisel J; Tegethoff SA; Last K; Rissland J; Smola S; Becker SL; Zemlin M; Meyer S; Papan C
Infection; 2023 Oct; 51(5):1349-1356. PubMed ID: 36757525
[TBL] [Abstract][Full Text] [Related]
8. TRAIL and IP-10 dynamics in pregnant women post COVID-19 vaccination: associations with neutralizing antibody potency.
Chen WC; Hu SY; Cheng CM; Shen CF; Chuang HY; Ker CR; Sun DJ; Shen CJ
Front Cell Infect Microbiol; 2024; 14():1358967. PubMed ID: 38572318
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory mediators profile in patients hospitalized with COVID-19: A comparative study.
Tufa A; Gebremariam TH; Manyazewal T; Getinet T; Webb DL; Hellström PM; Genet S
Front Immunol; 2022; 13():964179. PubMed ID: 35958594
[TBL] [Abstract][Full Text] [Related]
10. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
Agresti N; Lalezari JP; Amodeo PP; Mody K; Mosher SF; Seethamraju H; Kelly SA; Pourhassan NZ; Sudduth CD; Bovinet C; ElSharkawi AE; Patterson BK; Stephen R; Sacha JB; Wu HL; Gross SA; Dhody K
J Transl Autoimmun; 2021; 4():100083. PubMed ID: 33521616
[TBL] [Abstract][Full Text] [Related]
11. CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study.
Lorè NI; De Lorenzo R; Rancoita PMV; Cugnata F; Agresti A; Benedetti F; Bianchi ME; Bonini C; Capobianco A; Conte C; Corti A; Furlan R; Mantegani P; Maugeri N; Sciorati C; Saliu F; Silvestri L; Tresoldi C; ; Ciceri F; Rovere-Querini P; Di Serio C; Cirillo DM; Manfredi AA
Mol Med; 2021 Oct; 27(1):129. PubMed ID: 34663207
[TBL] [Abstract][Full Text] [Related]
12. A host signature based on TRAIL, IP-10, and CRP for reducing antibiotic overuse in children by differentiating bacterial from viral infections: a prospective, multicentre cohort study.
Papan C; Argentiero A; Porwoll M; Hakim U; Farinelli E; Testa I; Pasticci MB; Mezzetti D; Perruccio K; Etshtein L; Mastboim N; Moscoviz E; Ber TI; Cohen A; Simon E; Boico O; Shani L; Gottlieb TM; Navon R; Barash E; Oved K; Eden E; Simon A; Liese JG; Knuf M; Stein M; Yacobov R; Bamberger E; Schneider S; Esposito S; Tenenbaum T
Clin Microbiol Infect; 2022 May; 28(5):723-730. PubMed ID: 34768022
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of a host signature based on TRAIL, IP10, and CRP (MeMed BV) as infection biomarkers in intensive care units' patients. A retrospective observational study.
Steckiewicz KP; Wujtewicz MA; Okrągły M; Aszkiełowicz A; Dąbrowska M; Owczuk R
Clin Biochem; 2024 Apr; 126():110748. PubMed ID: 38490312
[TBL] [Abstract][Full Text] [Related]
14. An immune-protein score combining TRAIL, IP-10 and CRP for predicting severe COVID-19 disease.
Mastboim NS; Angel A; Shaham O; Ber TI; Navon R; Simon E; Rosenberg M; Israeli Y; Hainrichson M; Avni N; Reiner E; Feigin P; Oved K; Tadmor B; Singer P; Kagan I; Lev S; Diker D; Jarjou'I A; Kurd R; Ben-Chetrit E; Danziger G; Tegethoff SA; Papan C; Motov S; Shapira M; Stein M; Gottlieb TM; Eden E; Klein A
Cytokine; 2023 Sep; 169():156246. PubMed ID: 37327532
[TBL] [Abstract][Full Text] [Related]
15. A host-protein signature is superior to other biomarkers for differentiating between bacterial and viral disease in patients with respiratory infection and fever without source: a prospective observational study.
Ashkenazi-Hoffnung L; Oved K; Navon R; Friedman T; Boico O; Paz M; Kronenfeld G; Etshtein L; Cohen A; Gottlieb TM; Eden E; Chistyakov I; Srugo I; Klein A; Ashkenazi S; Scheuerman O
Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1361-1371. PubMed ID: 29700762
[TBL] [Abstract][Full Text] [Related]
16. Interferon-γ-induced protein 10 (IP-10) and serum amyloid A (SAA) are excellent biomarkers for the prediction of COVID-19 progression and severity.
Haroun RA; Osman WH; Eessa AM
Life Sci; 2021 Mar; 269():119019. PubMed ID: 33454365
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Markers in Hospitalized COVID-19 Patients: The Role of IP-10 and C-Reactive Protein.
Rizzi M; Costanzo M; Tonello S; Matino E; Casciaro FG; Croce A; Rizzi E; Zecca E; Pedrinelli A; Vassia V; Landi R; Bellan M; Castello LM; Minisini R; Mallela VR; Avanzi GC; Pirisi M; Lilleri D; Sainaghi PP
Dis Markers; 2022; 2022():3528312. PubMed ID: 35242241
[TBL] [Abstract][Full Text] [Related]
18. Early Prediction of Disease Progression in Patients with Severe COVID-19 Using C-Reactive Protein to Albumin Ratio.
Li Y; Li H; Song C; Lu R; Zhao Y; Lin F; Han D; Chen L; Pan P; Dai M
Dis Markers; 2021; 2021():6304189. PubMed ID: 34900028
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 severity and age increase the odds of delirium in hospitalized adults with confirmed SARS-CoV-2 infection: a cohort study.
LaHue SC; Escueta DP; Guterman EL; Patel K; Harrison KL; Boscardin WJ; Douglas VC; Newman JC
BMC Psychiatry; 2022 Feb; 22(1):151. PubMed ID: 35227231
[TBL] [Abstract][Full Text] [Related]
20. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
